Fig. 1From: BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancerBluePrint standard subtypes and clinical variables a Total group, b Hormone receptor-negative disease, c Hormone receptor-positive disease, d Node-negative disease, e Node-positive disease, f HER2 immunohistochemistry 1–2 + tumors, g HER2 immunohistochemistry 3 + tumors. HR hormone receptor, cN0 clinically node-negative, cN + clinically node-positive, HER2 IHC HER2 immunohistochemistry scoreBack to article page